Global firms turn to M&A in EVs and biotech to deepen China investment: KPMG

A KPMG survey shows three in four multinational corporations operating in China have maintained or increased investments this year, focusing on mergers and acquisitions in electric vehicles and biotechnology. Despite geopolitical tensions, only 1% are preparing to exit the market.

A KPMG survey published on Monday shows that three in four multinational corporations (MNCs) operating in mainland China have maintained or increased their investments in 2025, despite Washington stepping up efforts to decouple from Beijing and its allies following suit. The survey, polling 137 senior executives from global companies in the world's second-largest economy between June and September, revealed that only 1 per cent reported preparing to exit the market. About 20 per cent said they may reduce investment, while the rest had yet to decide.

Companies planning to expand said they would pursue greenfield investment, mergers and acquisitions or joint ventures to deepen their China presence. "We have seen a significant increase in mergers and acquisitions activities among MNCs in China over the past six months," said Mark Harrison, partner and co-head of multinational clients at KPMG in China.

"In consumer-facing sectors, amid fierce local competition and challenging market dynamics, MNCs are pursuing vertical integration by acquiring distributors, agents and original equipment manufacturers to better understand and serve Chinese consumers," Harrison added.

The survey found optimism in life sciences, healthcare and manufacturing, with half forecasting revenue growth. Key sectors include electric vehicles, biotechnology and semiconductors, even amid regulatory challenges like the US Biosecure Act.

Relaterade artiklar

Global institutional investors have built sizeable positions in China's largest biotech firms, including Innovent, 3SBio, WuXi Biologics, Jiangsu Hengrui, Akeso and BeOne. These companies, all constituents of the Hang Seng Biotech Index, are gaining importance on the global stage. Foreign investors, from sovereign wealth funds to industry players, are securing strategic stakes in their future success.

Rapporterad av AI

Chinese contract drug makers including WuXi AppTec, WuXi Biologics and WuXi XDC face a less certain long-term revenue outlook as US pharmaceutical companies reshore production amid US-China tensions. Cui Cui, head of healthcare research for Asia at Jefferies, said earnings visibility for 2026 and 2027 remains strong due to order backlogs, but longer-term order growth lacks clarity.

Deloitte released a report in Hong Kong stating that the Greater Bay Area spent about 28.9 billion yuan (US$4.2 billion) on basic research in 2024, accounting for just 5.67 per cent of total R&D spending, below China's national average of 6.9 per cent and far behind the US's 14.5 per cent and South Korea's nearly 15 per cent. Despite strong tech potential, the southern China cluster lags in basic research and original innovation, with talent gaps adding to challenges.

Rapporterad av AI

Mexico gears up for a pivotal 2026 in its economy, with potential in investment and mergers and acquisitions, but regulatory uncertainty poses risks. While nearshoring provides structural advantages, the local transaction slump contrasts with recovery in the United States. Experts emphasize the need for certainty to draw global capital.

 

 

 

Denna webbplats använder cookies

Vi använder cookies för analys för att förbättra vår webbplats. Läs vår integritetspolicy för mer information.
Avböj